Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

Bernstein said Novartis' decision to discontinue VHB937 for amyotrophic lateral sclerosis (ALS) on September 16 improves the commercial landscape for Zydus Lifesciences' Usnoflast.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Zydus Lifesciences (ZYDUSLIFE).
- Category: Stocks.
Why it matters
A routine update for Zydus Lifesciences. Use the price and stock snapshot to gauge how the market is responding.












